Abstract. GP85 is one of the most common hemopoietic isoforms of the cell adhesion molecule, CD44. CD44(GP85) is known to contain at least one ankyrin-binding site within its 70 aa cytoplasmic domain and to bind hyaluronic acid (HA) with its extracellular domain. In this study we have mapped the ankyrin-binding domain of CD44(GP85) by deleting various portions of the cytoplasmic region followed by expression of these truncated cDNAs in COS cells. The results of these experiments indicate that the ankyrin-binding domain resides between amino acids 305 and 355. Biochemical analyses, using competition binding assays and a synthetic peptide (NGGNGT-VEDRKPSEL) containing 15 aa between aa 305 and aa 320, support the conclusion that this region is required for ankryin binding. Furthermore, we have constructed a fusion protein in which this 15 aa sequence of CD44(GP85) is transplanted onto another transmembrane protein which does not bind ankyrin. Our results show that this fusion protein acquires the ability to bind ankyrin confirming that the sequence (~NGGNGTVEDRKPSE32°L) is a critical part of the ankryin-binding domain of CD44(GP85).
poietic isoforms of the cell adhesion molecule, CD44. CD44(GP85) is known to contain at least one ankyrin-binding site within its 70 aa cytoplasmic domain and to bind hyaluronic acid (HA) with its extracellular domain. In this study we have mapped the ankyrin-binding domain of CD44(GP85) by deleting various portions of the cytoplasmic region followed by expression of these truncated cDNAs in COS cells. The results of these experiments indicate that the ankyrin-binding domain resides between amino acids 305 and 355. Biochemical analyses, using competition binding assays and a synthetic peptide (NGGNGT-VEDRKPSEL) containing 15 aa between aa 305 and aa 320, support the conclusion that this region is required for ankryin binding. Furthermore, we have constructed a fusion protein in which this 15 aa sequence of CD44(GP85) is transplanted onto another transmembrane protein which does not bind ankyrin. Our results show that this fusion protein acquires the ability to bind ankyrin confirming that the sequence (~NGGNGTVEDRKPSE32°L) is a critical part of the ankryin-binding domain of CD44(GP85).
In addition, we have demonstrated that deletion of this 15 aa ankyrin-binding sequence from CD44(GP85) results in a drastic reduction (>190%) of HA-binding and HA-mediated cell adhesion. These findings strongly suggest that ankyrin binding to the cytoplasmic domain of CIM4(GP85) plays a pivotal role in regulating hyaluronic acid-mediated cell-cell and cell-extracellular matrix interactions.
T HE 85-kD mouse lymphocyte transmembrane glycoprotein, GP85 (also known as Pgp-1), is a well known T-cell differentiation antigen (66) . The cDNA sequence data indicate that mouse GP85 shares 72 % aa homology with human lymphocyte homing receptor CD44 (also called GP90 Hc~ antigen, ECMR HI, and homing cellular adhesion molecule [H-CAM] 1) (6, 18, 19, 34, 35, 51, 69, 70) . GP85 is one of the most common isoforms of CD44 found in all hemopoietic cells including T-cells, B-cells, macrophages, and granulocytes (33, 42, 66) . CIM4(GP85) has also been detected in many other cell types such as fibroblasts, epithelial ceils, and more recently endothelial cells (14, 17, 52) . To date at least 15 isoforms of CD44 have been identified. Some of these isoforms result from extensive, alternative exon splicing events (55, 57, 65) . CD44(GP85) has been shown to mediate the binding between lymphocytes and capillary high endothelial venules (HEV) during lymphocyte homing into lymphoid organs (6, 52) . In addition, CD44(GP85) is involved in T-and B-cell adhesion, cell aggregation and proliferation (30, 59) . Although the functional role of CIM4 is not fully understood, certain isoforms have been implicated recently in tumor metastasis (1, 2, 29, 31, 60) .
The extracellular matrix component, hyaluronic acid (HA), is one of the ligands specifically recognized by CD44-(GP85) (19, 32, 40, 54, 58, 67) . CD44(GP85) mediates HA-dependent cell adhesion in many cell types including leukocytes, fibroblasts, and macrophages (67) . HA-dependent cell adhesion plays an important role in mediating (a) interaction between stromal cells and lymphoid precursor cells in the bone marrow, (b) cell migration, and, (c) most likely, T-cell activation and B-cell maturation (19, 22, 30, 48, 63, 67) . Recent studies suggest that certain factors, such as protein kinase C (40) and the cytoplasmic domain of CD44-(GP85) (41) , may be important for the expression of HAbinding site(s). However, the molecular mechanisms involved in regulating the surface expression of HA-binding site(s) are not known.
Previously, we have demonstrated that the cytoplasmic domain of CD44(GP85) (,x,70 aa long) that is conserved >190% in most of the CD44 isoforms, is involved in ankyrin binding (16, 37) . The ankyrin-binding site(s) is expressed at a very early stage in the biosynthesis of CD44(GP85) (43) . Furthermore, the binding interaction between CD44(GP85) and ankyrin is highly specific and regulated by several factors in-eluding protein kinase C-mediated phosphorylation (38) , palmityolation (12) , and GTP binding (45) . The fact that ankyrin preferentially accumulates underneath CD44(GP-85) capped structures suggests that the formation of an ankyrin-CD44(GP85) complex is related to ligand-induced lymphocyte activation (16, 37). However, the physiological significance of this close association between ankyrin and CD44(GP85) during HA-mediated cell-matrix adhesion is not fully understood.
In this manuscript, we have mapped the ankyrin-binding domain of CD44(GP85) by constructing several cytoplasmic deletion mutants and expressing them in COS ceils. Our data indicate that deletion of a particular 15 aa sequence in the cytoplasmic domain of CD44(GP85) leads to a complete loss of ankyrin binding. Most interestingly, however, the deletion of ankyrin-binding domain also abolishes the HAbinding/HA-dependent cell adhesion capability of CD44-(GP85) without significantly affecting its overall cell surface expression. Therefore, binding of ankyrin to cytoplasmic domain of CD44(GP85) may be critically important for the proper surface expression of HA-mediated adhesion in cells containing CIM4(GP85).
Materials and Methods

Reagents
Rc/CMV plasmid containing the full-length mouse CD44(GP85/Pgp-1) eDNA clone was kindly provided by Dr. Eugene Butcher (Stanford University, CA [70] ). Mouse CD45(B 200; 64) eDNA was a gift from Dr. Ian Trowbridge (Salk Institute, La Julia, CA). pcDNA I was obtained from InVitrogen. An adaptor containing termination codons in all of the three possible reading frames with a Not I cohesive end was synthesized by the DNA facility (University of Miami, Miami, FL). Erythrocyte ankyrin, spectrin, pig brain fodrin, and 3H-HA were prepared as described previously (5, 28, 68) . Rat anti-CD44(GP85) monoclonal antibody IM7, which recognizes an epitope in the extracellular domain of CD44(GP85), and rat anti-CD45 monoclonal antibody I3/2.3 (kindly provided by Dr. Robert Hyman, Salk Institute) were purified from the hybridoma culture supernatant by sequential ammonium sulfate fractionatiun and DEAE-eellulose chromatography. Anti-CIM4(GP85) antibody, anti-CD45 antibody, ankyrin, and WGA (Sigma Chem. Co., St. Louis, MO) were coupled to CNBr-activated Sepharose beads (Pharmacia LKB Biotechnology, Piseataway, N J) according to the manufacturer's procedure. The region I and scramble peptides (described below) were synthesized by Dr. Eric Smith (University of Miami, Miami, FL).
Cell Culture
COS-7 cells were obtained from Amer. Type Culture Collection (Rockville, MD) and grown routinely in DMEM containing 10% FBS, 1% gintamine, 1% penicillin and 1% streptomycin. Mouse T-lymphoma BW5147 cells were cultured in DMEM containing 10% horse serum, 1% penicillin, and 1% streptomycin.
Protein Iodination
Ankyrin, fodrin, spectrin, anti-CD44(GP85) monoclonal antibody, purified lymphoma CD44(GP85), and surface proteins of COS-7 cells were iodihated using IodoGen as described (26) .
Deletion Mutagenesis
A 1.3-kb eDNA containing the entire mouse CD44(GP85) coding sequence cloned into pRc/CMV (InVitrogen Co.) was digested with Pst I, Sst I, Bcl I, and Tha I to generate mutants CD44(GPg5)A355, CD44(GPg5)A320, CD44(GP85)A305, and CD44(GP85)AA292. The 3' overhanging ends resulting from Psi I and Sst I digestions were blunt ended by I"4 DNA polymerase. Tha I digestion leaves blunt ended DNA fragments. These blunt ended fragments (Pst I, Sst I, and Tha I) were ligated to a synthetic Not I adaptor containing stop codons in all of the three possible reading frames. The DNA fragments were then digested with Hind 1II; the deleted CD44-(GP85) inserts were gel isolated and ligated into Hind Hi-Not I digested pcDNA I (InVitrogen Co.) for expression into COS cells. Bcl I digested DNA was further cut with Hind IlI without blunt ending and ligated directly into Hind I~-Baml-II digested pcDNA I to generate the CD44(GPgS)A305 mutant construct. The full length 1.3-kb CD(GP85) construct was also recloned into pcDNA I as a Hind HI-Not I fragment. All mutant constructs were characterized by restriction enzyme analyses and DNA sequencing.
COS Cell Transfection
COS-7 cells were transfected with pcDNA I plasmids containing various CD44(GP85) inserts using DEAE-dextran. Briefly, COS-7 cells were plated at a density of 2 × 106 cells per 100-ram dish and were transfected with 25/~g/dish plasmid DNA. Transfected cells were harvested after 48 h for analyses of CD44(GP85) expression.
Purification of CD44(GP83) Protein from Transfected COS Cells
Various CD44(GP85) proteins were purified from 8-10 100-ram dishes of COS cells transfected with one of the CD44(GP85) constructs. Control transfections consisted of either no DNA or pcDNA I vector DNA. The proteins were purified from either unlabeled or surface 125I-iabeled COS cells using non-ionic detergent Triton X-100 extraction followed by sequential WGA-Sepharose and anti-CD44(GP85) immunoafl~nity chromatographies, essentially according to the procedure described previously (43, 45) . Protein concentrations were determined using the protein assay reagent (BioPad Labs., Hercules, CA). Purity of the protein preparations was determined by SDS-PAGE followed by silver staining and/or autoradiography.
Binding of uSI-labeled Ankyrin to CD44(GP85) Proteins
Aliquots (10-20 ng protein) of both purified wild-type and mutant CD44(GP85) proteins bound to the anti-CD44(GP85) immunoaffinity beads were incubated in 0.5 ml of binding buffer (20 raM Tris.HCl pH 7.4, 150 mM NaCI, 0.1% BSA and 0.05 % Triton X-100) containing various concentrations (10--400 ng/ml) of 125I-labeled ankyrin (5,000 cpm/ng protein) at 4°C for 5 h. Non-specific binding was determined in presence of a 50-100-fold excess of unlabeled ankyrin and also by incubating the anti-CD44(GP85) immunobeads alone in the presence of the same concentration of 125I-labeled ankyrin. After binding, the immunobeads were washed extensively in binding buffer and the bead-bound radioactivity was counted. Non-specific binding was '~20% of the total binding.
Binding of us I-labeled Ankyrin/Fodrin/Spectrin to Synthetic Region I and Scramble Peptides
Nitrocellulose discs (l-cm diam) were coated with =1 ~g of either the region I (NGGNGTVEDRKPSEL) or a scramble peptide (GRNETNPEGSGL-DVK) at 4oc for 16 h. After coating, the unoccupied sites on the discs were blocked by incubation with a solution containing 20 mM Tris.HCl pH 7.4 and 0.3% BSA at 4°C for 2 h. The discs were then incubated with various concentrations (20, 40 , and 80 ng/ml) of 125I-labeled ankyrin/specttin/fodrin (=3,000 cpnffng) at 4°C for 2 h in 1 ml binding buffer (20 mM "Iris. HC1 pH 7.4, 150 mM NaCI, 0.2% BSA). After biDding~ the discs were washed three times in the binding buffer and the disc bound radioactivity was estimated. The non-specific binding was determined in the presence of a 100-fold excess of respective unlabeled ligends and was subtracted from the total binding. Non-specific binding was '~30% of the total binding. As controls, the ligands were also incubated with uncoated nitrocellulose discs to determine the binding observed due to the "stickyness" of various ligands. Nonspecific binding was observed in these controls.
Binding of WI-labeled Lymphoma CD44(GP85) to Ankyrin
CD44(GP85) was purified from the plasma membrane preparations of mouse T-lymphoma cells, by sequential WGA-Sepharose and anti-CD44-(GP85) immunoaflinity chro~ographies as described previously (43, 45) . 125I-labeled CD44(GP85) (=0.32 nM protein, 1.5 × lif t cpm/ng) was incubated with 30/~1 of ankyrin conjugated to Sepharose beads (=0.75/~g protein) in 0.5 ml of the binding buffer (described above). The binding was car-ried out in the presence or absence of various concentrations (1 riM-1/~M) of unlabeled competing synthetic region I peptide (NGGNGTVEDRKP-SEL) or the scramble peptide (GRNETNPEGSGLDVK) at 4°C for 5 h under equilibrium conditions. Equilibrium conditions were determined by performing time course (e.g., 1-10 h) of the binding studies. After binding, the beads were washed in the binding buffer and the bead bound radioactivity was determined. Nun-specific binding was determined in the presence of either a 100-fold excess of unlabeled ankyrin or using BSA-conjngated Sepharose beads. The non-specific binding was 20-30 % of the total binding and was subtracted from the total binding.
Binding of l~l-labeled Band 3 Cytoplasmic Domain Fragment to Ankyrin
The human band 3 protein cytoplasmic domain fragment (=43 kD) that binds ankyrin, was isolated from the erythrocyte ghost as described previously (5). The band 3 protein fragment was 125I-labeled to a specific activity of 6 x 104 cpm/ng. The binding of the 125I-labeled band 3 fragment (=0.5 nM) to ankyrin in the presence or absence of region I or the scramble peptides was carried out as described above.
Construction and Expression of CD45A826/CD44 (Reg. I) Fusion Protein
The mouse CD45(B200) eDNA cloned in pcDNA I was partially digested with Kpn I, followed by complete digestion with Xho I. An oligonucleotide adaptor (5'CAAC GG~~CAG TGGAAGACAC, GAAACC CAG-TGAGCTCTAA3~ and its complementary strand were synthesized by DNA facility, University of Miami, Miami, FL. The adaptor codes for mouse CD44(GP85) eDNA sequence corresponding to the 15 aa of the region I of the ankyrin-binding domain (69, 70) , a stop codon and Kpn I and Xho I cohesive ends. The adaptor was annealed to its complementary strand and cloned into Kpn I-Xho I digested CD45(B200)/pcDNA I plasmid. The resuiting construct, CD45A826/CD44(Reg.I) contains 826 aa of CIM5 and 15 aa of the region I of the ankyrin-binding domain. As a control, CD45-(B200)/pcDNA I was digested partially with Kpn I and completely with Xho I and ligated to an adaptor containing stop codon, and Kpn I and Xho I cohesive ends. Both CD45A826/CD44(Reg. I) and CD45A826 eDNA constructs were confirmed by sequencing. The CIM5A826 and CIMS-A826/CD44(Reg.I) constructs were transcribed and translated in vitro using the TNT coupled reticulocyte system (Promega Co., Madison, WI) and [35S]methionine (1,000 cpm/pmol). The in vitro translated proteins were purified by rat anti-CD45 immunoaffinity chromatography as described previously (44) . The expression and purity of the protein preparations were analyzed by SDS-PAGE followed by fluorography. As controls, CD44(GP85)363 and CI)44(GP85)A305 proteins were also synthesized in vitro and purified using anti-CD44(GP85) immunoaffinity chromatography. Both CIM5-and CIM4(GPg5)-related protein bound to immunoaffinity beads (=0.3 nM protein) were incubated with 30 ng of n5I-labeled ankyrin (3,000 cpm/ng) in 1 ml of the binding buffer (20 mM Tris.HC1 pH 7.4, 150 mM NaCI, 0.1% BSA, and 0.05 % Triton X-100) at 4°C for 5 h. Non-specific binding was detennined in the presence of 3 pg of unlabeled ankyrin and was subtracted. Non-specific binding was "v20% of the total binding. Other controls included binding of t25I-labeled ankyrin to anti-CD44(GP85) or anti-CIM5 immunobeads alone. No specific binding was observed in these controls.
Immunocytochemistry
COS cells (103 cells) were grown on coverslips and transfected with either various CD44(GP85) cDNAs or pcDNA I vector only as described above. Subsequently, cells were washed with PBS and fixed in PBS containing 2 % paraformaldehyde. Fixed cells were then stained with fluorescein-labeled HA (21) (5 #g/rnl) at room temperature for 30 rain followed by washing with PBS three times. To detect nonspecific HA binding, cells were incubated with fluorescein-labeled HA in the presence of an excess amount of HA (100 #g/ml). No labeling was observed in the control samples. The fluoresceinlabeled samples were excited with a Xenon 75-W bulb and examined using a Zeiss inverted microscope (63× oil immersion and epi-illumination). Cells were photographed with Kodak Tri-X film.
Binding of ~Sl-labeled Anti-CD44(GP85) Antibody and 3H-HA to COS Cells
COS cells (2 x 105 cells/35-mm dish) were transfected with either various CIM4(GP85) constructs or pcDNA I vector as described above. 48 h after the transfections, culture medium was removed and the cells were washed in PBS containing 0.2% BSA (binding buffer). The cells were then incubated with various concentrations of either 125I-labeled anfi-CD44(GP85) antibody (50, 100, and 200 ng/ml) or 3H-HA (0.3, 0.6, and 1.2 #g/rnl) in the binding buffer at room temperature or 4°C for 2 h. Nonspecific binding was determined in the presence of a 100-fold excess of unlabeled ligand. After binding, the cells were washed three times in binding buffer, and then solubilized in 1% SDS solution. The solubilized cell extracts were counted either in a gamma counter or a liquid scintillation counter.
Cell Adhesion Assay
COS cells were transfected with various constructs as described above. 48 h after transfection, cells were labeled with Tran[3SS]methionine (30 #Ci/ ml) for 2 h as described previously (43) . After labeling, cells were washed in PBS and incubated with PBS containing 5 mM EDTA at 37°C to obtain non-adherent, single cell suspensions. 1.2 x 106 cpm (=105 cells) were incubated in each well of a 24-well Coming culture plate coated with HA. The HA-coated plates were prepared by incubating the culture wells with 2 mg/ml rooster comb HA at 22°C for 16 h. HA-coated plates were rinsed sequentially three times with PBS containing 2% BSA and PBS before incubating with labeled cells. Labeled cells were incubated with HA-coated wells at 4°C for 60 rain. After incubation, wells were washed three times with PBS; the adherent cells were solubilized in PBS containing 1% SDS; and the well-bound radioactivity was determined by liquid scintillation counting. Non-specific binding was determined by including 200 ~tg/ml soluble HA during the incubation in the HA-coated wells. Non-specific binding was 10-15% of the total well-associated radioactivity and has been subtracted. To detect surface expression of CD44(GP85), we have performed surface iodination of COS cells (transfected with CD44(GP85) wild-type and various mutant cDNAs) followed by Triton X-100 extraction and sequential WGA-Sepharose and anti-CIM4(GP85) column chromatographies. Our results clearly indicate that the COS ceils transfected with the wild-type CD44(GP85)363 cDNA express a surface protein of 85 kD, whose molecular mass is the same as that of the most common hemopoietic isoform, GP85 (Fig. 2, lane 3) . Furthermore, we have found that the various truncated CD44(GP85) proteins are also expressed on the surface of the COS cells (Fig. 2, lanes 4-7) . Most importantly, the apparent molecular mass of the CD44(GP85) mutant proteins expressed on the COS cells appear to correspond very well with the molecular mass predicted by deletion mutation Figure 1. A schematic illustration of the in vitro mutagenesis approach used in this study. The four cytoplasmic deletion mutants of CIM4(GP85) were constructed according to the strategy described in the Materials and Methods. These constructs including CD44(GP85)363 (the wild-type containing full-length cDNA with no deletion), CIM4(GP85)A355 (a mutant cDNA with 8 aa deletion), CD44(GP85)A320 (a mutant cDNA with 43 aa deletion), CD44(GP85)A305 (a mutant cDNA with 58 aa deletion), and CIM4(GP85)A292 (a mutant cDNA with 71 aa deletion) were then subcloned into pcDNA I and transfected into COS cells to express proteins that encode 363, 355, 320, 305, and 292 aa, respectively.
Results
CD44(GP85) Cytoplasmic Domain Deletion Mutants and Their Expression in COS Cells
analysis ( Figs. 1 and 2) . Fig. 2, lane 2] ) reveal no surface expression of CD44(GP85). In addition, the isolation procedure used in this study (i.e., Triton X-100 extraction plus sequential WGA-Sepharose, anti-CD44[GP85] column chromatographies) allows us to obtain pure CD44(GP85) protein from COS cells transfected with various cDNAs. For example, COS ceils transfected with CD44(GP85)A320 cDNA reveal a single CD44(GP85) protein as shown by silver staining (Fig. 2, lane 8) . The same purification procedure was used to obtain purified CD44-(GP85) proteins from COS cells transfected with wild-type and the other three truncated CD44(GP85) cDNAs (data not shown). The availability of purified CD44(GP85) proteins from COS cells transfected with wild-type or mutant cDNAs has allowed us to perform in vitro ankyrin-binding assays for the purpose of mapping the ankyrin-binding domain of CD44(GP85).
Mapping the Ankyrin-binding Domain of CD44(GP85)
We have shown previously that the cytoplasmic domain of CD44(GP85) is involved in the interaction with ankyrin, both in vivo and in vitro (16, 37) . Several posttranslational modifications appear to be required for effective CD44-(GP85)-ankyrin binding (12, 38, 45) . In this study we have used an in vitro binding assay to determine the effect of the four cytoplasmic domain deletions on the ability of CD44-(GP85) to bind ankyrin in order to better define the ankyrin-binding domain of CD44(GP85). Specifically, purified 
equilibrium-binding conditions. As shown in Fig. 3 A, ankyrin binds specifically to both CD44(GP85)363 (wild-type) (Fig. 3 A, a) and CD44(GP85)A355 (mutant with an 8 aa deletion) (Fig. 3 A, b) proteins in a dose-dependent and saturable manner. Scatchard plot analyses of the equilibrium-binding isotherms shown in Fig. 3 A indicate that ankyrin binds to these proteins at a single site (Fig. 3  B, a and b) with high affinity (an apparent dissociation constant [Kd] of =1 nM) (Fig. 3 B, a and b ) similar to that obtained for the mouse lymphoma GP85 protein (13) . These results indicate that the COOH-terminal 8 cytoplasmic aa may be deleted without affecting ankyrin binding. An additional deletion of the sequence between aa 320 and 355 (i.e., CD44[GP85]A320 [mutant with a 43 aa deletion]) causes a slight reduction in binding of n5I-labeled ankyrin compared to the wild-type, CD44(GP85)363, or the mutant, CD44(GP85)A355 proteins (Fig. 3 A, c) . This mutant protein also binds ankyrin with a slightly lower affinity (I~ =2.6 nM) (Fig. 3 B, c) . These results suggest that ankyrinbinding affinity has been reduced when 43 COOH-terminal aa are deleted. The sequence between aa 320 and 355 (designated as "region 1/" of the cytoplasmic domain of CD44-[GP85]) shares a great deal of sequence homology with CD44 proteins from various species (Table I A (Fig. 3 A, d and e). These findings indicate that the ankyrin-binding domain of CIM4(GP85) must reside between aa 305 and 355. The 15 aa (~NGGNGTVEDRK-PSE32°L) sequence is designated as the region I of the cytoplasmic domain of CD44(GP85) ( Table I A) . This region appears to share a great deal of homology with various CD44 proteins from different species (Table I A) (7, 51, 55, 65, 70 [GenBank Ace. No. X66862]). Since the deletion of both region I and 11 but not region 11 alone shows a complete loss of ankyrin binding, it suggests that the region I may be an important part of the ankyrin-binding domain of CD44(GP85).
To examine whether region I of the cytoplasmic domain of CD44(GP85) is involved in ankyrin binding, we have tested the ability of a synthetic region I peptide (e.g., NGGNGT-VEDRKPSEL) to bind various cytoskeletal proteins. As shown in Fig. 4 (panel/) , the region I peptide binds ankyrin specifically and in a dose-dependent manner (Fig. 4, panel  1 A) . The binding of this peptide to ankyrin is specific since it does not bind other cytoskeletal proteins such as spectrin (Fig. 4 [panel 1 B] or fodrin (Fig. 4 [panel 1 C] ). A control peptide (GRNETNPEGSGLDVK), containing a scrambled sequence with the same amino acid composition as that of the synthetic region I peptide, does not bind either ankyrin or spectrin or fodrin (Fig. 4 [panel 2, A, B, and C]) . To further analyze the role of region I in ankyrin binding, we have used the synthetic peptide corresponding to region I to compete the binding of pure mouse T-lymphoma CD44(GP85) to ankyrin. As shown in Fig. 5 A, the synthetic peptide competes effectively with CD44(GP85) to bind ankyrin with an apparent inhibition constant (Ki) =50 nM. However, the control peptide with the scrambled sequence does not corn- 
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pete at all with CIM4(GP85) to bind ankyrin (Fig. 5 A) . Since human erythrocyte band 3 protein is a well established ankyrin-binding protein (3, 4, 20) , we have also tested whether the region I peptide would compete with an ankyrinbinding fragment (=43 kD) derived from the cytoplasmic domain of band 3 (40) for ankyrin binding. As shown in Fig.  5 B, the region I peptide also competes with the 43-kD ankyfin-binding domain of erythrocyte band 3 in a dose-dependent manner with an apparent inhibition constant (K0 =200 nM. The scrambled sequence peptide does not compete with the 43-kD fragment of band 3 for ankyrin binding (Fig. 5 B) . (a)
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The sequence comparison of the ankyrin-binding domain of CD44(GP85) with similar sequences found in other ankyrin-binding proteins. The (1) indicates a perfect match. The bold letters and C) indicate a conserved substitution. Gaps are introduced for the alignment.
These results suggest that region I is a critical part of the ankyrin-binding domain of CD44(GP85). Furthermore, we have constructed a fusion protein (designated as CD45A826/CD44 [Reg.I]) (Table II) in which the 15 aa sequence of region I of CD44(GP85) is transplanted onto another transmembrane protein, the truncated CD45 molecule, CIM5A826 (64) . CD45, a leukocyte common antigen (also called GP180 or T-200) has been shown to bind fodrin (a spectrin-like protein) but not ankyrin (15, 62, 64) . The cDNAs encoding various proteins (e.g., CD45A826, CD45A826/CD44[Reg.I], CD44[GP851363, and CD44-[GP85]A305) are transcribed and translated in vitro using the TNT reticulocyte lysate system which generates unglycosylated polypeptides. We have previously shown that the unglycosylated precursor of CD44(GP85) binds ankyrin equally well as the mature CD44(GP85) (43) . The polypeptides synthesized by in vitro transcription and translation are purified by anti-CD44(GP85) or anti-CIM5 immunoaflinity chromatography. The CIM5A826 eDNA encodes a 105-kD protein corresponding to a polypeptide encoding 826 aa (Fig. 6 A) . This protein does not display any ankyrin-binding property (Table II) . The fusion protein CD45A826/CD44-(Reg.I) shows a slight increase in molecular mass (=2 kD) compared to CD45A826 protein (Fig. 6 B) . Most importantly, it is able to bind ankyrin (Table II) (GP85)363 protein (Fig. 6 C, and Table 1I ). In addition, as expected the 37-kD unglycosylated CIM4(GP85)A305 protein does not bind ankyrin (Fig. 6 D, and Table I_I) . Taken together, these findings support the contention that the region I sequence (NGGNGTVEDRKPSEL) is a critical part of the ankyrin-binding domain of CD44(GP85).
Effect of Cytoplasmic Deletions of CD44(GP85) on HA-mediated Binding and Adhesion in COS Cells Transfected with Various CD44(GP85) Constructs
In this set of experiments, we have attempted to correlate the effect of the ankyrin-binding domain with the expression of HA-interaction capability by COS cells transfected with various CIM4(GP85) constructs. Using fluorescein-HA staining techniques, we have found that HA-binding sites are readily detectable as large patched structures on the surface of COS cells transfected with CIM4(GP85)363 and CIM4(GP85)-A355 cDNAs (Fig. 7, A and B) . A reduction in HA binding, revealed as small clusters (Fig. 7 C) is observed in COS cells expressing the CD44(GP85)A320 protein. Most importantly, we have found that cells expressing CIM4(GP85)A305 and CD44(GP85)A292 proteins, which lack the complete ankyrin-binding domain (Fig. 3 A) , do not exhibit any detectable fluorescein-HA binding (Fig. 7, D and E) . Further analysis, using fluorescence-conjugated anti-CD44(GP85) antibody staining techniques reveals that a uniform distribution pattern (not clustered or patched) of CD44 on the surface of COS cells expressing CD44(GP85)A305 and CD44(GP85)-A292 proteins (data not shown). This result suggests that ankyrin is required for the collection of CD44 into clusters or patches.
The differential expression of HA-binding in COS cells transfected with different CD44(GP85) mutant constructs is further corroborated by 3H-HA-binding assays and cell adhesion to HA-coated plates. Our results indicate that the mutant CD44(GP85)A355 protein displays 3H-HA binding (Fig. 8 B, b ) and cell adhesion (Table HI) at levels comparable to those of the wild-type protein (Fig. 8, A, b and Table  1 ]/). There is a slight reduction in both 3H-HA binding (Fig. 8 C, b ) and cell adhesion (Table lid in Table HI ). As controls, COS cells either transfected with peDNA I vector alone or untransfected were also analyzed and show a background level of HA-mediated binding (data not shown) and cell adhesion to HA-coated plates (Table IR) . To verify that the loss of HA-binding sites in the COS ceils transfected with certain mutants is not due to a failure to express CD44(GP85) on the cell surface, we have also quantitatively determined the expression of CD44(GP85) by incubating the COS cells with nSI-labeled anti-CD44-(GP85) antibody. Fig. 8 shows that COS cells transfected with various constructs express comparable amounts of CD44(GP85) (Fig. 8 A a, B a, C a, D a, and E a); only a small reduction in CD44(GP85) expression (=15%) is observed in COS cells transfected with either CD44(GP85)-A320 ( Fig. 8 C, a) , CD44(GP85)A305 (Fig. 8 D, a) or CIM4(GPg5)A292 cDNAs ( Fig. 8 E, a) when compared to the wild-type (Fig. 8 A, a) and CD44(GP85)A355 expression ( Fig. 8 B, a) . Since all of these mutant proteins are expressed on the COS cell surface (Figs. 2, 7 , and 8), these resuits strongly suggest that ankyrin binding to the cytoplasmic domain of CD44(GP85) is important for both high affinity HA-binding and HA-mediated cell adhesion.
Discussion
CD44(GP85) binds extracellular matrix components such as HA at its NH2-terminal domain and contains an ankyrinbinding site within its 70 aa long COOH-terminal domain (38, 69, 70) . It has been suggested that ankyrin binding to CIM4(GP85) is involved in lymphocyte activation (8, 9) . However, at the present time, the relationship between the two functional domains, i.e., the ankyrin-binding and HAmediated binding/adhesion, is not well understood. In this work, we have identified the ankyrin-binding domain in CD44(GP85). Furthermore, we have shown that the ankyfin-binding domain in the cytoplasmic tail of CIM4 (GP85) is very important for HA-binding and HA-mediated adhesion functions.
Ankyfin is known to link various transmembrane proteins to actin network through interaction with spectfin or fodrin (a spectrin-like protein) (4, 46) . For example, in erythrocytes, ankyfin connects band 3 anion exchange protein to spectrin (3, 4, 20) . In non-erythrocytes, ankyfin is shown to be associated with a number of physiologically important proteins including the Na+/K+ ATPase (49, 50) , voltagedependent (25) and amiloride-sensitive Na+ channels (57), inositol 1,4,5 triphosphate 0P3) receptor (10) and CIM4-(GP85) (16, 37) possibly via fodrin. Among these proteins, the interaction between ankyfin and CIM4(GP85) may be considered as one of the most well understood in non-erythrocytes. Our laboratory has extensively characterized the interaction between CIM4(GP85) and ankyrin (12, 13, 16, 37, 38, 43, 45) . However, the aa sequence of CD44(GP85) involved in ankyrin binding has not yet been identified.
Since the cytoplasmic domain of CD44(GP85) is relatively short (=70 aa) in comparison to other well characterized ankyfin-binding proteins (e.g., erythrocyte band 3 [39, 47] , it offers us an excellent opportunity to map the ankyrin-hinding site(s) of CIM4[GP85]). Our deletion mutation analysis indicates that the ankyrin-binding domain of CIM4(GP85) resides in aa 305 and 355. However, at least two regions within this domain contribute to ankyrin binding. Region I, contains 15 aa between 305 and 320; and region II contains 35 aa between 320 and 355 (Table I A). The region II appears to be required for the high affinity ankyrin binding, since its deletion (e.g., CIM4(GP85)A320 protein) results in a 2-2.5-fold decrease in the dissociation constant for ankyrin binding. This region is conserved in various CD44(GP85) proteins from different species (Table I A) . Nevertheless, no sequence homology is detected between CD44's region II and other ankyrin-binding proteins (e.g., band 3 and Na+/K + ATPase, etc.) using a Best fit program (Genetics Computer Group Inc., 24). It is possible that this region contains regulatory domains (e.g., protein kinase C-mediated phosphorylation, GTP binding, GTPase activity, etc.) responsible for the upregulation of CD44(GP85)-ankyrin interaction (38, 45) . Deletion of these regulatory domains could result in the observed reduction of high affinity binding between CD44-(GP85) and ankyfin. The deletion of both region I and II of CIM4(GP85) leads to a complete loss of ankyrin binding. This suggests that the region I (~NGGNGTVEDRKPSE320L) is required for ankyrin binding. The fact that (a) the region I peptide (but not the scrambled peptide) binds ankyrin specifically and in a dose-dependent manner (Fig. 4) ; (b) the synthetic region I peptide (but not the scrambled peptide) competes effectively with mouse T-lymphoma CD44(GP85) for ankyrin binding (Fig. 5) ; and (c) a fusion protein expressing this sequence acquires the ability to bind ankyrin (Table ID , clearly demonstrates that the region I sequence must be a required part of the ankyrin-binding domain of CIM4(GP85).
Since the region I peptide also competes effectively (Ki =200 riM) with the 43-kD ankyrin-binding fragment of human band 3 protein, a region I-like sequence may also be present in band 3 protein that is required for ankyrin binding. Using a Best fit (Genetics Computer Group Inc., 24) program to compare region I and the 43-kD ankyrin-binding do-main of band 3 protein, we have found a sequence between aa 178 and 192 has limited sequence similarity with region I (Table I B, a) . It is interesting to note that this band 3 sequence partially overlaps with a region (between aa 174 and 186) of band 3 that is known to be involved in ankyrin binding (20) . However, it has been suggested that the region between aa 174 and 186 of band 3 protein alone is not sufficient to account for all the high affinity interaction between the cytoplasmic domain (43-kD fragment) and ankyrin (20) . After further sequence comparison between region I and the 43-kD fragment, we have found a second sequence in band 3 (aa 203-216) that also shares some sequence similarity with region I (Table I B, b) . It is possible that both of these sequences are necessary for the high affinity binding observed between the cytoplasmic domain of band 3 and ankyrin (20) . In addition, sequence comparison reveals two segments, aa 109-123 and aa 627-640 of Na+/K+-ATPase o~ subunit (another well characterized ankyrin-binding protein) (49, 50, 56) , that share some sequence similarity with region I (Table  I C ). The sequence between aa 627 and aa 640 appears to be included in one of two ankyrin-binding domains of Na+/ K+-ATPase a subunit as shown by Devarajan et al. recently (23) . However, at the present time no biochemical evidence is available to support the notion that another segment such as aa 1094423 of the Na+/K+-ATPase o~ subunit is required for ankyrin binding. Further studies are needed to precisely map the ankyrin-binding domain(s) in the Na+/K+-ATPase.
In this manuscript, we have presented a new mechanism which implicates the cytoskeletal protein, ankyrin, in the regulation of HA-mediated functions. There appears to be a strong correlation between the presence of an ankyrin-binding domain in the cytoplasmic tail of CD44(GP85) and the expression of HA-binding and HA-mediated adhesion functions. For example, cells expressing the mutant protein CIM4(GP85)A320 that lacks region II of the ankyrinbinding domain displays a moderate decrease in both ankyrin-binding affinity and HA-mediated functions. More importantly, ceils expressing the mutant proteins CD44-(GP85)4305 and CIM4(GP85)A292 that lack the entire ankyrin-binding domain (both region I and ID, display no ankyrin binding and nearly a complete loss of HA-binding and HA-mediated adhesion functions. These findings strongly imply that the intracellular interaction of CIM4(GP85) with ankyrin is required for its adhesion functions on the cell surface.
The fact that HA-binding and HA-mediated adhesion functions can be readily inhibited by cytoskeletal drugs, such as cytochalasin D (a microfilament inhibitor) or W-7 (a calrnodulin inhibitor), suggests an involvement of actin and myosinmediated contraction in HA-mediated functions (13). The involvement of the cytoskeleton in controlling the exposure of high affinity binding sites for hormones such as insulin and interleukin-2 has also been reported previously (11, 36) . Similar observations have also been made in other adhesionrelated events. For example, the cytoskeleton binding domain within the cytoplasmic tail of the integrin B1 subunit is involved in the formation of focal adhesion plaques (53) . Furthermore, cytoskeleton binding is also important for the function of a number of other adhesion molecules (e.g., ICAM-1, N-CAM, and E-eadherin) (27) . Taken together, these findings strongly suggest that the binding of membraneassociated cytoskeletal proteins, such as ankyrin, to the cytoplasmic domain of CD44(GP85) is critically important in regulating various cell-cell and cell-extracellular matrix interactions.
